Publications HYPO Avril 2024- mars 2025

Craniopharyngiomes

BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort study. De Alcubierre D, Gkasdaris G, Mordrel M, Joncour A, Briet C, Almairac F, Boetto J, Mouly C, Larrieu-Ciron D, Vasiljevic A, Villa C, Sergeant C, Ducray F, Feuvret L, Chanson P, Baussart B, Raverot G, Jouanneau E.Eur J Endocrinol. 2024 Aug 5;191(2):251-261. doi: 10.1093/ejendo/lvae091.

Diagnosis and management of children and adult craniopharyngiomas: A French Endocrine Society/French Society for Paediatric Endocrinology & Diabetes Consensus Statement. Cuny T, Reynaud R, Raverot G, Coutant R, Chanson P, Kariyawasam D, Poitou C, Thomas-Teinturier C, Baussart B, Samara-Boustani D, Feuvret L, Villanueva C, Villa C, Bouillet B, Tauber M, Espiard S, Castets S, Beckers A, Amsellem J, Vantyghem MC, Delemer B, Chevalier N, Brue T, André N, Kerlan V, Graillon T, Raingeard I, Alapetite C, Raverot V, Salenave S, Boulin A, Appay R, Dalmas F, Fodil S, Coppin L, Buffet C, Thuillier P, Castinetti F, Vogin G, Cazabat L, Kuhn E, Haissaguerre M, Reznik Y, Goichot B, Bachelot A, Kamenicky P, Decoudier B, Planchon C, Micoulaud-Franchi JA, Romanet P, Jacobi D, Faucher P, Carette C, Bihan H, Drui D, Rossignol S, Gonin L, Sokol E, Wiard L, Courtillot C, Nicolino M, Grunenwald S, Chabre O, Christin-Maître S, Desailloud R, Maiter D, Guignat L, Brac de la Perrière A, Salva P, Scavarda D, Bonneville F, Caron P, Vasiljevic A, Leclercq D, Cortet C, Gaillard S, Albarel F, Clément K, Jouanneau E, Dufour H, Barat P, Gatta-Cherifi B. Ann Endocrinol (Paris). 2025 Feb;86(1):101631.doi: 10.1016/j.ando.2024.07.002.

Predominantly cystic craniopharyngiomas: Current management approaches, outcomes and limitations.Calvanese F, Jannelli G, Sergeant C, Manet R, Feuvret L, Ducray F, Raverot G, Jouanneau E.Best Pract Res Clin Endocrinol Metab. 2025 Feb 5:101981. doi: 10.1016/j.beem.2025.101981.

Acromégalie

Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE). Giustina A, Uygur MM, Frara S, Barkan A, Biermasz NR, Chanson P, Freda P, Gadelha M, Haberbosch L, Kaiser UB, Lamberts S, Laws E, Nachtigall LB, Popovic V, Reincke M, van der Lely AJ, Wass JAH, Melmed S, Casanueva FF.Pituitary. 2024 Aug;27(4):381-388. doi: 10.1007/s11102-024-01397-w.

Acromegaly: Incidence, patient characteristics and treatment patterns in a 10-year nationwide retrospective hospital cohort study. Fauchier G, Laurent E, Maione L, Lecuyer AI, Herbert J, Pierre-Renoult P, Cloix L, Chanson P, Ducluzeau PH, Grammatico-Guillon L.Ann Endocrinol (Paris). 2024 Dec;85(6):589-595. doi: 10.1016/j.ando.2024.09.002.

Remission of Acromegaly: The Sooner the Better. Cuny T, Maione L, Störmann S.Clin Endocrinol (Oxf). 2024 Dec;101(6):602-604. doi: 10.1111/cen.15147.

Paltusotine: A Step Toward Precision Medicine in Acromegaly. Castinetti F, Brue T.J Clin Endocrinol Metab. 2025 Feb 18;110(3):e897-e898. doi: 10.1210/clinem/dgae489.

Changes in multi-modality management of acromegaly in a tertiary centre over 2 decades. Amodru V, Sahakian N, Piazzola C, Appay R, Graillon T, Cuny T, Morange I, Albarel F, Vermalle M, Regis J, Dufour H, Brue T, Castinetti F.Pituitary. 2024 Jun;27(3):294-302. doi: 10.1007/s11102-024-01387-y.

New treatments for acromegaly: Is a revolution underway? Cristante J, Castinetti F.Ann Endocrinol (Paris). 2025 Feb 15;86(2):101710. doi: 10.1016/j.ando.2025.

Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine.Gadelha MR, Casagrande A, Strasburger CJ, Bidlingmaier M, Snyder PJ, Guitelman MA, Boguszewski CL, Buchfelder M, Shimon I, Raverot G, Tóth M, Mezősi E, Doknic M, Fan X, Clemmons D, Trainer PJ, Struthers RS, Krasner A, Biller BMK.J Clin Endocrinol Metab. 2024 Dec 18;110(1):228-237. doi: 10.1210/clinem/dgae385.

Ectopic acromegaly with tumoral range hyperprolactinemia and apoplexy with a dramatic regression of pituitary hyperplasia. Gupta A, Kasaliwal R, Das L, Sharma SK, Kaur V, Vasiljevic A, Raverot V,

Korbonits M, Dutta P.Front Endocrinol (Lausanne). 2024 Oct 10;15:1473167. doi: 10.3389/fendo.2024.1473167.

Does size really matter? A closer look at the absolute size of growth hormone-secreting pituitary adenomas. Schilbach K, Raverot G.Pituitary. 2024 Oct;27(5):440-443. doi: 10.1007/s11102-024-01449-1. Epub 2024 Aug 30.PMID: 39212829

Cushing

Cushing-induced Male Hypogonadism: Deciphering a Prevalent Yet Understudied Relationship. Maione L, Jayasena CN.J Clin Endocrinol Metab. 2024 Nov 22:dgae731. doi: 10.1210/clinem/dgae731.

Personalized Noninvasive Diagnostic Algorithms Based on Urinary Free Cortisol in ACTH-dependant Cushing's Syndrome. Lavoillotte J, Mohammedi K, Salenave S, Furnica RM, Maiter D, Chanson P, Young J, Tabarin A.J Clin Endocrinol Metab. 2024 Oct 15;109(11):2882-2891. doi: 10.1210/clinem/dgae258.

Prolonged adrenal insufficiency following discontinuation of osilodrostat treatment for intense hypercortisolism. Ferriere A, Salenave S, Puerto M, Young J, Tabarin A.Eur J Endocrinol. 2024 Jan 3;190(1):L1-L3. doi: 10.1093/ejendo/lvad167.

Medical management pathways for Cushing's disease in pituitary tumors centers of excellence (PTCOEs). Giustina A, Uygur MM, Frara S, Barkan A, Biermasz NR, Chanson P, Freda P, Gadelha M, Haberbosch L, Kaiser UB, Lamberts S, Laws E, Nachtigall LB, Popovic V, Schilbach K, Lely AJV, Wass JAH, Melmed S, Casanueva FF.Pituitary. 2025 Jan 29;28(1):23. doi: 10.1007/s11102-024-01485-x.

Mineralocorticoid axis activity and cardiac remodeling in patients with ACTH-dependent Cushing's syndrome. Wolf P, Travers S, Domenig O, Baron S, Blanchard A, Bouazizi K, Kachenoura N, Salenave S, Poglitsch M, Redheuil A, Trabado S, Young J, Chanson P, Kamenický P.Endocr Connect. 2025 Jan 27;14(2):e240617. doi: 10.1530/EC-24-0617.

Desmopressin is a safe and effective secretagogue to replace corticotropin-releasing hormone in petrosal sinus sampling. Piazzola C, Graillon T, Girard N, Dufour H, Brue T, Castinetti F.Ann Endocrinol (Paris). 2024 Dec 19;86(2):101678. doi: 10.1016/j.ando.2024.101678.

Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease. Pivonello R, Fleseriu M, Newell-Price J, Shimatsu A, Feelders RA, Kadioglu P, Tabarin A, Brue TC, Geer EB, Piacentini A, Pedroncelli AM, Biller BMK.J Endocrinol Invest. 2024 Oct;47(10):2437-2448. doi: 10.1007/s40618-024-02359-6.

A promising new direct immunoassay for urinary free cortisol determination. Raverot V, Hablouj K, Perrin P, Lasolle H, Raverot G.Clin Chem Lab Med. 2024 Dec 17;63(5):e139-e142. doi: 10.1515/cclm-2024-1192. Print 2025 Apr 28.PMID: 39679630

Pathogenic role of acyl coenzyme A binding protein (ACBP) in Cushing's syndrome. Pan H, Tian AL, Chen H, Xia Y, Sauvat A, Moriceau S, Lambertucci F, Motiño O, Zhao L, Liu P, Mao M, Li S, Zhang S, Joseph A, Durand S, Aprahamian F, Luo Z, Ou Y, Shen Z, Xue E, Pan Y, Carbonnier V, Stoll G, Forveille S, Leduc M, Cerrato G, Cerone A, Maiuri MC, Castinetti F, Brue T, Wang H, Ma Y, Martins I, Kepp O, Kroemer G.Nat Metab. 2024 Dec;6(12):2281-2299. doi: 10.1038/s42255-024-01170-0. Epub 2024 Nov 22.PMID: 39578649

Prolactinome

Increase in Testosterone Levels and Improvement of Clinical Symptoms in Eugonadic men With a Prolactin-secreting Adenoma. Carlier L, Chanson P, Cazabat L, Daclin S, Salenave S, Hage M, Trabado S, Young J, Maione L. J Endocr Soc. 2024 Jul 16;8(9):bvae135. doi: 10.1210/jendso/bvae135.

Evidence for somatic mutation screening on aggressive prolactinomas. Theodoropoulou M, Petersenn S, Chanson P, Raverot G.Nat Rev Endocrinol. 2024 Oct;20(10):565-566. doi: 10.1038/s41574-024-01010-x.

Prolactin: structure, receptors, and functions. Chasseloup F, Bernard V, Chanson P.Rev Endocr Metab Disord. 2024 Dec;25(6):953-966. doi: 10.1007/s11154-024-09915-8.

Menopause has a beneficial influence on the evolution of prolactinomas. A study of 99 patients. Constantinescu SM, Nava CM, Chasseloup F, Alexopoulou O, Chanson P, Maiter D.J Clin Endocrinol Metab. 2025 Mar 7:dgaf152. doi: 10.1210/clinem/dgaf152.

Autres Adénomes/ Tumeurs hypophysaires

Outcome of non-functioning ACTH pituitary tumors: silent does not mean indolent. Sahakian N, Goetz L, Appay R, Graillon T, Raingeard I, Piazzola C, Regis J, Castinetti F, Brue T, Dufour H, Cuny T.Pituitary. 2024 Oct;27(5):644-653. doi: 10.1007/s11102-024-01428-6.

Aggressive pituitary tumors and carcinomas: medical treatment beyond temozolomide. DE Alcubierre D, Carretti AL, Ducray F, Jouanneau E, Raverot G, Ilie MD.Minerva Endocrinol (Torino). 2024 Sep;49(3):321-334. doi: 10.23736/S2724-6507.23.04058-7. Epub 2024 Jan 19.PMID: 38240681

Diagnosis and management of pituitary adenomas in children and adolescents. Maiter D, Chanson P, Constantinescu SM, Linglart A.Eur J Endocrinol. 2024 Sep 30;191(4):R55-R69. doi: 10.1093/ejendo/lvae120.

Clinical and therapeutic implications of cavernous sinus invasion in pituitary adenomas. Lefevre E, Chasseloup F, Hage M, Chanson P, Buchfelder M, Kamenický P.Endocrine. 2024 Sep;85(3):1058-1065. doi: 10.1007/s12020-024-03877-2.

Reassessing the role of the p.(Arg304Gln) missense AIP variant in pituitary tumorigenesis. Loughrey PB, Mothojakan NB, Iacovazzo D, Arni A, Aflorei ED, Arnaldi G, Barlier A, Beckers A, Bizzi MF, Chanson P, Dal J, Daly AF, Dang MN, David A, de Oliveira Andrade M, Else T, Elston MS, Evans A, Ferrau F, Fica S, Flanagan D, Gadelha MR, Grossman AB, Kapur S, Khoo B, Kumar AV, Kumar-Sinha C, Lechan RM, Ludman M, Metherell LA, Miljic D, Mourougavelou V, Musat M, Occhi G, Owens M, Pascanu I, Pinheiro SVB, Radian S, Ribeiro-Oliveira A Jr, Schöfl C, Patel KA, Hernández-Ramírez LC, Korbonits M.Eur J Endocrinol. 2025 Mar 12:lvaf044. doi: 10.1093/ejendo/lvaf044.

Identifying research priorities for pituitary adenoma surgery: an international Delphi consensus statement. Newall N, Valetopoulou A, Khan DZ, Borg A, Bouloux PMG, Bremner F, Buchfelder M, Cudlip S, Dorward N, Drake WM, Fernandez-Miranda JC, Fleseriu M, Geltzeiler M, Ginn J, Gurnell M, Harris S, Jaunmuktane Z, Korbonits M, Kosmin M, Koulouri O, Layard Horsfall H, Mamelak AN, Mannion R, McBride P, McCormack AI, Melmed S, Miszkiel KA, Raverot G, Santarius T, Schwartz TH, Serrano I, Zada G, Baldeweg SE, Kolias AG, Marcus HJ; PitCop Collaborative.Pituitary. 2025 Mar 5;28(2):36. doi: 10.1007/s11102-025-01502-7.

Déficits hypophysaires

Gonadotropic status in adult women with pituitary stalk interruption syndrome. Terray A, Baussart B, Zins M, Goldberg M, Kab S, Cazabat L, Brière M, Brue T, Barraud S, Reznik Y, Christin-Maitre S, Illouz F, Raverot G, Young J, Raffin-Sanson ML, Hage M.Eur J Endocrinol. 2024 Jun 5;190(6):501-508. doi: 10.1093/ejendo/lvae064.

Long-acting growth hormone in the management of GHD in France. Linglart A, Coutant R, Polak M, Nicolino M.Arch Pediatr. 2024 Aug;31(6):357-364. doi: 10.1016/j.arcped.2024.03.009.

Diagnosis and management of congenital hypopituitarism in children. Castets S, Thomas-Teinturier C, Villanueva C, Amsellem J, Barat P, Brun G, Quoc EB, Carel JC, De Filippo GP, Kipnis C, Martinerie L, Vergier J, Saveanu A, Teissier N, Coutant R, Léger J, Reynaud R.Arch Pediatr. 2024 Apr;31(3):165-171. doi: 10.1016/j.arcped.2024.01.003.

Classes and predictors of reversal in male patients with congenital hypogonadotropic hypogonadism: a cross-sectional study of six international referral centres. Dwyer AA, McDonald IR, Cangiano B, Giovanelli L, Maione L, Silveira LFG, Raivio T, Latronico AC, Young J, Quinton R, Bonomi M, Persani L, Seminara SB, Lee CS.Lancet Diabetes Endocrinol. 2024 Apr;12(4):257-266. doi: 10.1016/S2213-8587(24)00028-7.

Phenotype and genotype of 23 patients with hypopituitarism and pathogenic GLI2 variants. Aouchiche K, Charmensat C, Morgane P, Teinturier C, Bretones P, Brac de la Perriere A, Layet V, Bouhours-Nouet N, Vantyghem MC, Haine E, Nunes-Sanchez ML, Camard O, Baron S, Castinetti F, Barlier A, Brue T,

Reynaud R, Saveanu A; Genhypopit Network.Eur J Endocrinol. 2025 Feb 1;192(2):110-118. doi: 10.1093/ejendo/lvaf015.

Modeling corticotroph deficiency with pituitary organoids supports the functional role of *NFKB2* in human pituitary differentiation. Mac TT, Fauquier T, Jullien N, Romanet P, Etchevers H, Barlier A, Castinetti F, Brue T**.**Elife. 2024 Nov 28;12:RP90875. doi: 10.7554/eLife.90875.

Quality of life of chronically ill children and adolescents: a cross-sectional study. Perreard P, Castets S, Aouchiche K, Bernoux D, Bruno D, Cailliez M, Clave S, Coste ME, De Leusse C, Duvant P, Garaix F, Gauche L, Marquant E, Roman C, Roquelaure B, Rouvière CR, Vergier J, Tsimaratos M, Berbis J, Fabre A, Reynaud R. Arch Pediatr. 2024 Oct;31(7):439-445. doi: 10.1016/j.arcped.2024.04.007.

Autres

Deciphering the Presentation and Etiologies of Hypophysitis Highlights the Need for Repeated Systematical Investigation. Miquel L, Testud B, Albarel F, Sahakian N, Cuny T, Graillon T, Brue T, Dufour H, Schleinitz N, Kaplanski G, Ebbo M, Castinetti F.J Clin Endocrinol Metab. 2024 Sep 23:dgae664. doi: 10.1210/clinem/dgae664.

PIT-EASY survey: validation of the European Pituitary Pathology Group proposal for reporting pituitary neuroendocrine tumors. Birtolo MF, Jouinot A, Vasiljevic A, Boulagnon-Rombi C, Asioli S, Bousdira G, Tetka LMM, Perbet R, Maurage CA, Appay R, Figarella-Branger D, Gauchotte G, Sturm N, Baussart B, Roncaroli F, Bertherat J, Brue T, Villa C; CRMR HYPO, FIRENDO (French National Healthcare Network for Rare Endocrine Diseases).Virchows Arch. 2024 Sep;485(3):407-415. doi: 10.1007/s00428-024-03849-x.

Updates on the genetics of multiple endocrine neoplasia. Sahakian N, Castinetti F, Romanet P, Reznik Y, Brue T.Ann Endocrinol (Paris). 2024 Apr;85(2):127-135. doi: 10.1016/j.ando.2023.11.005.

Letter to the editor: "Primary" hypophysitis and the benefits of glucocorticoids, a still unresolved question. Miquel L, Testud B, Castinetti **F.**Eur J Endocrinol. 2025 Jan 6;192(1):L1-L2. doi: 10.1093/ejendo/lvae164.

Challenges in molecular diagnosis of multiple endocrine neoplasia. Romanet P, Charnay T, Sahakian N, Cuny T, Castinetti F, Barlier A.Front Endocrinol (Lausanne). 2024 Sep 27;15:1445633. doi: 10.3389/fendo.2024.1445633.

PFMG2025-integrating genomic medicine into the national healthcare system in France. PFMG2025 contributors.Lancet Reg Health Eur. 2025 Jan 6;50:101183. doi: 10.1016/j.lanepe.2024.101183.